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Ras gene mutations have been implicated in the 
pathogenesis of a variety of human tumors. Mutated 
ras genes have been isolated from human melanoma 
cell lines, but subsequent studies indicated that ras 
gene mutations may be a rare event in melanocytic 
lesions. Recently, a study reported a high frequency 
of ras mutations correlated with increasing invasion 
level. To address this inconsistency in the published 
data, we analyzed 50 primary melanomas to correlate 
invasion level, tumor thickness, histologic typing, 
and body localization with point mutations around 
co dons 12/13/61 of the three ras genes. After micro-
dissection of paraffin-embedded tumor tissue, ras 
gene mutations were analyzed by direct sequencing 
of tumor DNA amplified by polymerase chain reac-
tion. Only two melanomas exhibited ras gene muta-
tions, one sample containing a transition from A to G 
Ras proto-oncogene proteins belong to the Ras superfamily of 
GTP-binding proteins involved in the regulation of different 
intracellular processes, including cellular proliferation and differ-
entiation, intracellular vesicular trafficking, oxidase generation, 
and cytoskeletal control (reviewed in [1]). The ras proto-oncogene 
family-H-ras, Ki-ras, and N-ras-encodes 21-kD proteins that are 
sinUlar structurally, functionally, and immunologically [2]. Activa-
tion of p21 ras has been shown to be regulated by a large number 
of guanine nucleotide-releasing stimulatory or GTPase-activating 
inhibitory proteins. GTP hydrolysis , resulting in inactive p21 ras, 
may be impaired by single amino acid substitutions at positions 12, 
13, or 61. In vitro mutagenesis studies have demonstrated that these 
substitutions represent a common mechanism of ras activation and 
subsequent oncogenic cellular transformation [3]. 
Activated ras genes have been detected in a wide variety of 
human tumors [2] and may be involved in tumor progression of 
malignant melanoma, as indicated repeatedly by ill vitro mutagenesis 
studies [4-8]. M elanoma cell lines showed predominantly N-ras 
mutations at codon 61 and, at a lower frequency, H-ras mutations. 
Subsequent studies of primary tissue specimens revealed point 
mutations almost universally in the N-ras gene; H-ras and Ki-ras 
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at position 2 of N-ras codon 61 and the other exhibi-
ting a transversion from C to A at position 1 and a 
transition from A to G at position 2 ofN-ras codon 61. 
Both tumors were classified as Clark level IV, with a 
tumor thickness of 2.5 and 1.2 mm, respectively. 
Both were typed as superficial spreading melanoma 
and localized to intermittently sun-exposed body 
sites. The low frequency of ras mutations in malig-
nant melanoma and the lack of ras mutations in 
melanoma samples from constantly sun-exposed 
body sites argue against the hypothesis of ras muta-
tions as a marker of progression in malignant mela-
noma and the suggestion that ras mutations occur 
predominantly in melanomas from constantly sun-
exposed body sites. Key words: polymerase chain reaction/ 
DNA sequencing/paraffin-embedded tissue. ] Invest Derma-
tol 104:868-871, 1995 
mutations may also occur at low frequency [7,9-12]. However, the 
frequency of mutated N-ras genes in cultured and noncultured 
malignant melanoma cells has been demonstrated to be low, 
ranging from 5% to 20% [7,9,11]. T hus, it has been concluded that 
activated ras genes may play no fundamental role in malig1lant 
melanoma development [7,9]. These results, however, did not 
exclude the possibility that ras gene alterations may be restricted to 
a subset of melanomas, as indicated by analysis of primary mela-
noma samples from sun-exposed body sites [11]. 
Recently, one study specifying tumor thickness and invasion 
levels and analyzing tumor localization on body sites reported a 
high frequency of ras mutations correlated with increasing Clark 
stage, i.e ., 19% Ul C lark level II, 53% Ul C lark level Ill, 39% Ul 
Clark level IV, and 50% Ul C lark level V tumors [13J. Another 
study specifying histologic type and tumor localization reported a 
low frequency (6%) ofN-rns mutations Ul primary melanomas [14]. 
To address this inconsistency in the published data, we analyzed a 
series of 50 prunary cutaneous malig113nt melanomas for mutations 
around codons 12, 13, and 61 of the H-ras, Ki-rns, and N-rns genes 
by direct sequencing of microdissected, polymerase chain reaction 
(PCR)-amplified tumor DNA and correlated these results with 
clinicopathologic data including Clark level, Breslow thickness, 
typing, and tumor localization 011 body sites. 
MATERIALS AND METHODS 
Tissue Specilnens Fifty cutaneous malignant melanomas from 50 pa-
tients, fixed in 10% buffered formalin (PH 7.0) and embedded in paraffin 
wax, were taken from the files of the Department of Dermatology, 
University of Essen. For all tissue samples, cwucopathologic data including 
Clark level, Breslow thickness, . typing, and localization on body sites were 
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available from the clinical records. Histologic diagnosis and classification of 
all specimens were reexamined independently by two of the authors. These 
data are summarized in Table I. 
Microdissection and Preparation of Genomic DNA Microdissection 
was perfonlled as described [15] to reduce nonlesional tissue material, 
which may contribute to wild-type DNA. One to five serial paraffin sections 
were cut from each specimen, depending on tl,e total area of tl1C section 
processed. Histologic examination before and after microdissection con-
finned the analysis of representative areas of tl,e respective lesion (Fig 1). 
Only ti ssue sections witll C lark level and Breslow thickness according to 
those obtained by routine histologic analysis were included in tllis study. 
Remailllng tumor tissue was placed in a reaction tube and subjected to DNA 
preparation as described [15,16] . 
Direct Sequencing of PeR-Amplified DNA PCR of Ha-ms codon 
12/ 13 /61, Ki-ras codon 61, and N-ras codon 12113/61 was perfonned with 
10 J.tl of sample DNA as described previously [17,18]. Ki- ras codon 12113 
was amplified in a nested PCR procedure essentially as described [15] . PCR 
products were purified by separation on a 5% non-denaturing polyacryl-
amide gel, elution, and precipitation according to standard tecluliques [19] . 
Purified PCR products were sequenced according to the dideo"J' chain 
termination method [20] with amplification primers used as sequencing 
primers. 
Figure 1. S100 immunostaining of 
microdissected tissue section reveals 
at least 80% tumor cells. Original tissue 
section before microdissection, with hema-
to"J'lin 31ld eosin stain (a) ; and nllcrodis-
sected tissuc scction with S100 immunos-
taining and hemalawl counterstaining (b). 
Bars, 300 J.tm. 
b 
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Table I. Tissue Samples Analyzed 
Paralne tcr n 
Clark level 
I 7 
II 10 
III 13 
IV 11 
V 9 
Total 50 
Breslow thickness (0101) 
< 0.75 13 
0.75-1.5 17 
> 1.5 20 
Total 50 
Type" 
III S;/U 7 
LMM 8 
SSM 22 
NM 13 
Total 50 
" LMM, lentigo maligna melanoma: SSM, supcrfici31 spreading melanoma; NM. 
nodu.lar melanoma. 
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Figure 2. N-ras gene point mutations observed in two of 50 malig-
n an t melanoma tissues analyzed. Sequence analysis of N-ms 61 wild 
type; case I, exhibi ting a transition from A . T to G . C at position 2; and 
case 2, cxlUbiting a transversion from C ' G to A . T at position 1 and a 
transition from A' T to G ' C at position 2. Both cases 1 and 2 contain 
wild- type DNA sequence; anti-sense N - ras sequences are shown . 
RES U LTS AN D DISCUSSIO N 
Ras m utations were de tected in two of 50 m elanomas studied (Fig 
2) as point m utatio ns exclusively at N - ras codon 61. Case 1 
(classified as C lark level IV, Breslow thickness 2 .5 mm, superfi cial 
spreading growth pattem) exhibited a transitio n from A . T to G . C 
at position 2 of codon 61 of the N -rns gene (C AA ~ CGA) (Fig 2), 
w hich resul ts in a substitutio n of glutamine wi th arginine in the 
deduced amino acid sequence . Case 2 (cl assified as C lark level IV, 
Breslow thickness 1.2 mm , superficial spreading grow th pattem) 
exhibited two differen t muta tio ns in the same codon. At p osition 1 
of N -ras codon 61, a transversio n fro m C ' G to A . T w as present, 
w hereas position 2 exhibi ted a transition from A . T to G . C (Fig 
2). T his mutational spectrum m ay indicate a do uble po int mutatio n 
of a single tumor cell clone (CAA ~ AGA) or m ay be due to the 
p resence of two different m elano m a cell clones (CAA ~ AAA and 
CAA ~ CGA). M onoclonali ty would result in a deduced amino 
acid substitution of glu tam in e with arginin e, whereas bi clo nality 
would result in substitutions w ith lys ine aJld arginine, re spectively. 
All other codons analyzed (codons 12113/6 1 of the H-rns, Ki-ras, 
and N-rns genes) were fo und to be free of structural alte rations. 
O ur results indicate that the presence of activated ras genes is rare 
in maligmll1 t m elanom a and con firm previo us studies reporting on 
low levels of mutated ras genes detected in melanom a cell s either 
by d irect analysis, after short-term cultu re , or by transforming 
activity in ;/1 " jlro mutagenesis studies [7,9 ,1 4,21]. In accordance 
with these studies, our results emphasize the firs t two positions of 
N-ras codon 61 as the site of ras gene mutatio ns in m alignant 
m elanoma [7,9,11 ,21 ], wi th a resultillg p21 ras mutation by substi-
tu tion of glutamine with arginine Or lysin e [7 ,9, 14] . T hese substi -
tu tions seem to have particular bio logic significance beca use they 
are known to convert normal p21 ras into o ne with tran sfo rming 
activ ity [2,3 ]. 
Because ultraviolet (UV)-induced lesio ns seem to be targeted 
predominantly to dipyrimidine sites [22], it has been sp ecul ated that 
mutations of N -ras codon 61 resul t from UV irradiation [1 1] . Both 
ras-mutated melanoma samples exhibited N - ras mutations and w ere 
removed from body sites in te rmi ttently exposed to UV irradiation 
(case 1, upper ann; case 2, sole of the le ft foot) [11,23,24] . T hus, 
interm ittent U V irradi ation m ay represen t a possible indu cer of ras 
m utations. However, the lack of ras mutations in m elano ma 
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samples from constantly sun-exposed body sites as well as in the 
lentigo m aligna melano ma subtype , which is associated with lo ng-
term constant UV exposure, argues aga inst the sugges tion that ras 
mutations occur predominantl y in m elano mas from constantly 
sun-exposed body sites [11]. 
In our study, the low frequency of ras gene mutatio ns was no t 
due to a low sensitivi ty level of o ur sequen cing approach. T itratio n 
studies by mixing cloned wild-type and mutated faS gene sequences 
re vealed a detection limit o f 5% to 10% of mutated ras gene D N A 
for every amplification type aJld m ay result in the detec tio n of at 
least 10% to 20% of mutated cells in ti ssue samples. T his has been 
. demonstrated previously for Ki-ras codon 12 [15] . T he sensitivi ty of 
our approach w as furth er enhanced by care ful and histo logically 
controll ed microdissection of tumor material , with preservation of 
the deep es t pathology of the tumor sample. C ontro l immunostain-
ing of raJldomly selected solitary tissue sections with S-100 anti-
body (Dian ova, H amburg, Germ an y) after microdissection re-
vealed a portion of at least 80% tumor cells in the m aterial subjected 
to DNA extraction (Fig 1). 
According to previous studies on primary ti ssue specimens o f 
malignant m elanoma, o ur study provides no evidence to support 
the hypothesis of ras mutations as a marker of progression in human 
malignant melan o m a, as indicated by results of B all el al [13] that 
w ere obtained by oligonucleotide hybridization assay. Similar 
divergencies have been reported previously for Ki-ras and N-ras 
gene mutations in m elanocytic lesio ns; high levels o f I<i-ras and 
N-ras gene mutations obtained by oligonucleotide hybridization 
assay could not be confirmed by direct sequencing approaches 
[10,1 2,14]. As discussed comprehensively by Albino eI al [1 2], these 
diffe rences may be du e to a number of param eters kno wn to be 
critical in the oligonucleotide hybridiza tion assay, including hybrid-
iza tion conditions, use of tetram ethylammonium-chIOl;de- based 
solu tions in abroga ting melting-temperatu re di ffe rences of o ligonu-
cleotides with different purine conten t, and the use o f o ligonucle-
otides m atched for similar structural features . It m ay be that o ne or 
m ore of these facto rs m ay be responsibl e fo r the di ffe rences 
between previous data and th ose o f BaJJ e/ al [13]. 
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